Patents by Inventor Ramila Philip

Ramila Philip has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MHC class I associated peptides for prevention and treatment of zika virus
    Patent number: 11931407
    Abstract: The invention provides a vaccine composition comprising a flavivirus peptide comprising one or more CD8+ T cell epitopes, wherein the peptide is attached to a nanoparticle.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: March 19, 2024
    Assignee: EMERGEX VACCINES HOLDING LIMITED
    Inventor: Ramila Philip
  • MHC CLASS I ASSOCIATED PEPTIDES FOR PREVENTION AND TREATMENT OF MULTIPLE FLAVI VIRUS
    Publication number: 20240050548
    Abstract: The invention provides a vaccine composition comprising a flavi peptide comprising one or more CD8+ T cell epitopes.
    Type: Application
    Filed: October 13, 2023
    Publication date: February 15, 2024
    Inventor: Ramila Philip
  • MHC CLASS I ASSOCIATED PEPTIDES FOR PREVENTION AND TREATMENT OF MULTIPLE FLAVI VIRUS
    Publication number: 20230346908
    Abstract: The invention provides a vaccine composition comprising a flavi peptide comprising one or more CD8+ T cell epitopes.
    Type: Application
    Filed: June 9, 2023
    Publication date: November 2, 2023
    Inventor: Ramila Philip
  • MHC class I associated peptides for prevention and treatment of multiple flavi virus
    Patent number: 11690904
    Abstract: The invention provides a vaccine composition comprising a flavi peptide comprising one or more CD8+ T cell epitopes.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: July 4, 2023
    Inventor: Ramila Philip
  • MHC CLASS I ASSOCIATED PEPTIDES FOR PREVENTION AND TREATMENT OF ZIKA VIRUS
    Publication number: 20230129352
    Abstract: The invention provides a vaccine composition comprising a flavivirus peptide comprising one or more CD8+ T cell epitopes, wherein the peptide is attached to a nanoparticle.
    Type: Application
    Filed: August 29, 2022
    Publication date: April 27, 2023
    Inventor: Ramila Philip
  • MHC class I associated peptides for prevention and treatment of zika virus
    Patent number: 11426457
    Abstract: The invention provides a vaccine composition comprising a flavivirus peptide comprising one or more CD8+ T cell C1 epitopes, wherein the peptide is attached to a nanoparticle.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 30, 2022
    Assignee: EMERGEX VACCINES HOLDING LIMITED
    Inventor: Ramila Philip
  • UNIVERSAL INFLUENZA VACCINE COMPOSITIONS
    Publication number: 20220233679
    Abstract: The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.
    Type: Application
    Filed: December 28, 2021
    Publication date: July 28, 2022
    Inventor: Ramila Philip
  • Pharmaceutical compositions comprising dengue virus-specific multiple HLA-binding T cell epitopes
    Patent number: 11344614
    Abstract: Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. Herein, we report novel, naturally processed and presented MHC class I restricted epitopes, a subset of which binds to and activates T cells in both an HLA-A2 and HLA-A24 restricted manner.
    Type: Grant
    Filed: September 29, 2018
    Date of Patent: May 31, 2022
    Assignee: Emergex Vaccines Holding Ltd.
    Inventor: Ramila Philip
  • Universal influenza vaccine compositions
    Patent number: 11273216
    Abstract: The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: March 15, 2022
    Assignee: EMERGEX VACCINES HOLDING LIMITED
    Inventor: Ramila Philip
  • MHC Class I Associated Hepatitis B Peptides
    Publication number: 20220054631
    Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of Hepatitis B virus (HBV) infection, and discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against HBV infection. The peptide and/or proteins of the invention may be used as a therapeutic drug to stimulate the immune system to recognize and eliminate HBV infection in infected cells or as a vaccine for the prevention of disease.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 24, 2022
    Applicant: Emergex Vaccines Holding Ltd.
    Inventor: Ramila Philip
  • Universal influenza vaccine compositions
    Patent number: 11235053
    Abstract: The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: February 1, 2022
    Assignee: EMERGEX VACCINES HOLDING LIMITED
    Inventor: Ramila Philip
  • MHC class I associated hepatitis B peptides
    Patent number: 11191828
    Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of Hepatitis B virus (HBV) infection, and discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against HBV infection. The peptide and/or proteins of the invention may be used as a therapeutic drug to stimulate the immune system to recognize and eliminate HBV infection in infected cells or as a vaccine for the prevention of disease.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: December 7, 2021
    Assignee: Emergex Vaccines Holding Ltd.
    Inventor: Ramila Philip
  • MHC CLASS I ASSOCIATED PEPTIDES FOR PREVENTION AND TREATMENT OF MULTIPLE FLAVI VIRUS
    Publication number: 20210361760
    Abstract: The invention provides a vaccine composition comprising a flavi peptide comprising one or more CD8+ T cell epitopes.
    Type: Application
    Filed: January 4, 2019
    Publication date: November 25, 2021
    Inventor: Ramila Philip
  • REVERSE PEPTIDE VACCINE
    Publication number: 20210299241
    Abstract: The invention relates to vaccine compositions comprising peptides encoded by an open reading frame (ORF) encoded by at least part of the genome of a ssRNA virus in the opposite sense to positive sense RNA capable of translation, and the use of such compositions for the treatment and prevention of viral infection.
    Type: Application
    Filed: May 20, 2019
    Publication date: September 30, 2021
    Inventors: Ramila Philip, Richard David Perrins, Xiaofang Huang, Thomas Rademacher, Christopher Upton
  • VACCINE COMPOSITIONS
    Publication number: 20210283237
    Abstract: The invention provides a vaccine composition comprising a filovirus peptide comprising one or more CD8+ T cell epitopes, wherein the peptide is attached to a nanoparticle
    Type: Application
    Filed: March 29, 2019
    Publication date: September 16, 2021
    Inventors: Laurens Rademacher, Thomas Rademacher, Ramila Philip
  • VACCINE COMPOSITIONS
    Publication number: 20210093708
    Abstract: The invention provides a vaccine composition comprising a filovirus peptide comprising one or more CD8+ T cell epitopes, wherein the peptide is attached to a nanoparticle.
    Type: Application
    Filed: March 29, 2019
    Publication date: April 1, 2021
    Inventors: Laurens Rademacher, Thomas Rademacher, Ramila Philip
  • MHC CLASS I ASSOCIATED PEPTIDES FOR PREVENTION AND TREATMENT OF ZIKA VIRUS
    Publication number: 20200268871
    Abstract: The invention provides a vaccine composition comprising a flavivirus peptide comprising one or more CD8+ T cell C1 epitopes, wherein the peptide is attached to a nanoparticle.
    Type: Application
    Filed: September 21, 2018
    Publication date: August 27, 2020
    Inventor: Ramila Philip
  • Dengue Virus Specific Multiple HLA Binding T Cell Epitopes For The Use Of Universal Vaccine Development
    Publication number: 20200101150
    Abstract: Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. Herein, we report novel, naturally processed and presented MHC class I restricted epitopes, a subset of which binds to and activates T cells in both an HLA-A2 and HLA-A24 restricted manner.
    Type: Application
    Filed: September 29, 2018
    Publication date: April 2, 2020
    Applicant: Emergex Vaccines Holding Ltd.
    Inventor: Ramila Philip
  • Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection
    Patent number: 10556929
    Abstract: Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHR) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. The present invention incorporates immunoproteomics to uncover novel HLA-A2 specific epitopes derived from Dengue Virus (DV)-infected cells. These epitopes are conserved with epitope-specific CTLs cross-reacting against all four DV serotypes. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in Dengue virus (DV) infection, and serves as a universal vaccine candidate complementary to current vaccines.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: February 11, 2020
    Assignee: Emergex Vaccines Holding Ltd.
    Inventor: Ramila Philip
  • UNIVERSAL INFLUENZA VACCINE COMPOSITIONS
    Publication number: 20190321460
    Abstract: The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.
    Type: Application
    Filed: January 3, 2018
    Publication date: October 24, 2019
    Inventor: Ramila Philip